.

Name : DGEHS-243769-MR VIRENDER SINGH

Lab No. : 172309386 Age : 64 Years
Ref By : SELF.... Gender : Male
Collected : 4/2/2023 9:00:00AM Reported : 4/2/2023 2:57:28PM
A/c Status : P Report Status : Final
Collected at : WALK IN PSC HANUMAN ROAD Processed at : LPL-VASANT KUNJ LAB
REGAL BUILDING CANNUAGHT PLACE-110001 NELSON MANDELA MARG, BUILDING No.1,
L.S.C., SECTOR-B, POCKET-7, VASANT
KUNJ, NEW DELHI-110070

Test Report

Test Name Results Units Bio. Ref. Interval

LIPID PROFILE, BASIC, SERUM

Cholesterol Total 148 mg/dL <200.00

(CHO-POD)
Triglycerides 103 mg/dL <150.00
(GPO)
HDL Cholesterol 38 mg/dL >40.00
(Homogenous assay)
LDL Cholesterol,Direct 108 mg/dL <100.00
(Homogenous assay)
VLDL Cholesterol 21 mg/dL <30.00
(Calculated)
Non-HDL Cholesterol 110 mg/dL <130.00
(Calculated)

Interpretation
-----------------------------------------------------------------------------------
| NATIONAL LIPID | TOTAL | TRIGLYCERIDE | LDL CHOLESTEROL |NON HDL |
| ASSOCIATION | CHOLESTEROL | in mg/dL | in mg/dL |CHOLESTEROL |
| RECOMMENDATIONS | in mg/dL | | |in mg/dL |
| (NLA-2014) | | | | |
|-------------------|---------------|--------------|-----------------|--------------|
| Optimal | <200 | <150 | <100 | <130 |
|-------------------|---------------|--------------|-----------------|--------------|
| Above Optimal | - | - | 100- 129 | 130 - 159 |
|-------------------|---------------|--------------|-----------------|--------------|
| Borderline High | 200-239 | 150-199 | 130-159 | 160 - 189 |
|-------------------|---------------|--------------|-----------------|--------------|
| High | >=240 | 200-499 | 160-189 | 190 - 219 |
|-------------------|---------------|--------------|-----------------|--------------|
| Very High | - | >=500 | >=190 | >=220 |
-----------------------------------------------------------------------------------

Note
1. Measurements in the same patient can show physiological & analytical variations. Three serial
samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.
2. Lipid Association of India (LAI) recommends screening of all adults above the age of 20 years for
Atherosclerotic Cardiovascular Disease (ASCVD) risk factors especially lipid profile. This should be
done earlier if there is family history of premature heart disease, dyslipidemia, obesity or other risk
factors
3. LAI recommends, for routine screening, a fasting lipid profile is not mandatory. Both fasting and
non-fasting lipid profiles are important for managing Indian patients with dyslipidemia. In most patients,
there is usually a clinically unimportant increase in TG concentrations 2-6 hours after eating normal
meals. Non fasting levels are required to determine post prandial hypertriglyceridemia which may be

*172309386* Page 1 of 5
.

Name : DGEHS-243769-MR VIRENDER SINGH

Lab No. : 172309386 Age : 64 Years
Ref By : SELF.... Gender : Male
Collected : 4/2/2023 9:00:00AM Reported : 4/2/2023 2:57:28PM
A/c Status : P Report Status : Final
Collected at : WALK IN PSC HANUMAN ROAD Processed at : LPL-VASANT KUNJ LAB
REGAL BUILDING CANNUAGHT PLACE-110001 NELSON MANDELA MARG, BUILDING No.1,
L.S.C., SECTOR-B, POCKET-7, VASANT
KUNJ, NEW DELHI-110070

Test Report

Test Name Results Units Bio. Ref. Interval

more significant predictor of CVD risk. Fasting lipid profile is required if:
· Non-fasting triglycerides >400 mg/dL
· Known hypertriglyceridaemia on treatment
· Recovering from hypertriglyceridaemic pancreatitis
· Starting medications that cause severe hypertriglyceridaemia
· Additional laboratory tests are requested that require fasting or morning samples (e.g. fasting
glucose, therapeutic drug monitoring etc)

ASCVD Risk Stratification & Treatment goals in Indian population

Indians are at very high risk of developing Atherosclerotic Cardiovascular (ASCVD). Among the various
risk factors for ASCVD such as dyslipidemia, Diabetes Mellitus, sedentary lifestyle, Hypertension,
smoking etc, dyslipidemia has the highest population attributable risk for MI both because of direct
association with disease pathogenesis and very high prevalence in Indian population. Accordingly,
monitoring lipid profile regularly for effective management of dyslipidemia remains one of the most
important healthcare targets for prevention of ASCVD. In addition, estimation of ASCVD risk is an
essential, initial step in the management of individuals requiring primary prevention of ASCVD ie
individuals who do not have pre-existing ASCVD. In the context of lipid management, such a risk
estimate forms the basis for several key therapeutic decisions, such as the need for and the
aggressiveness of statin therapy. LAI recommends LDL cholesterol as primary target and Non HDL
cholesterol as co-primary treatment target. The goal for Non HDL Cholesterol in those with increased
triglyceride is 30 mg/dL above that set for LDL Cholesterol. Apolipoprotein B is an optional, secondary
lipid target for treatment once LDL & Non HDL goals have been achieved. Additional testing for
Apolipoprotein B, Lp(a ) & hsCRP should be considered among patients with moderate risk for ASCVD
for risk refinement

Treatment Goals as per Lipid Association of India 2020

*172309386* Page 2 of 5
.

Name : DGEHS-243769-MR VIRENDER SINGH

Lab No. : 172309386 Age : 64 Years
Ref By : SELF.... Gender : Male
Collected : 4/2/2023 9:00:00AM Reported : 4/2/2023 2:57:28PM
A/c Status : P Report Status : Final
Collected at : WALK IN PSC HANUMAN ROAD Processed at : LPL-VASANT KUNJ LAB
REGAL BUILDING CANNUAGHT PLACE-110001 NELSON MANDELA MARG, BUILDING No.1,
L.S.C., SECTOR-B, POCKET-7, VASANT
KUNJ, NEW DELHI-110070

Test Report

Test Name Results Units Bio. Ref. Interval

--------------------------------------------------------------------------------------------
| | CONSIDER THERAPY | TREATMENT GOAL |
| ASCVD RISK |-------------------------------------|----------------------------------------|
| CATEGORY@ | LDL CHOLESTEROL| NON HDL CHLOESTEROL| LDL CHOLESTEROL | NON HDL CHLOESTEROL|
| | (LDL-C)(mg/dL) | (NON HDL-C) (mg/dL)| (LDL-C)(mg/dL) |(NON HDL-C) (mg/dL |
|--------------|----------------|--------------------|-------------------|--------------------|
|Extreme (A) | >=50 | >=80 |<50 (Indispensable)| <80 |
| | | |<30 (Optional) | |
|--------------|----------------|--------------------|-------------------|--------------------|
|Extreme (B) | >=30 | >=60 | <30 | <60 |
|--------------|----------------|--------------------|-------------------|--------------------|
| Very High | >=50 | >=80 | <50 | <80 |
|--------------|----------------|--------------------|-------------------|--------------------|
| High | >=70 | >=100 | <70 | <100 |
|--------------|----------------|--------------------|-------------------|--------------------|
| Moderate | >=100 | >=130 | <100 | <130 |
|--------------|----------------|--------------------|-------------------|--------------------|
| Low | >=130* | >=160* | <100 | <130 |
---------------------------------------------------------------------------------------------
* In low risk patient, consider therapy after an initial non-pharmacological intervention for at least 3 months

@To know your risk category click on bit.ly link sent on your registered mobile number, answer the
questionnaire, the ASCVD risk report can be downloaded from website

*172309386* Page 3 of 5
.

Name : DGEHS-243769-MR VIRENDER SINGH

Lab No. : 172309386 Age : 64 Years
Ref By : SELF.... Gender : Male
Collected : 4/2/2023 9:00:00AM Reported : 4/2/2023 2:57:28PM
A/c Status : P Report Status : Final
Collected at : WALK IN PSC HANUMAN ROAD Processed at : LPL-VASANT KUNJ LAB
REGAL BUILDING CANNUAGHT PLACE-110001 NELSON MANDELA MARG, BUILDING No.1,
L.S.C., SECTOR-B, POCKET-7, VASANT
KUNJ, NEW DELHI-110070

Test Report

Test Name Results Units Bio. Ref. Interval

GLUCOSE, FASTING (F) AND POST MEAL, PLASMA

(Hexokinase)
Glucose Fasting 139.00 mg/dL 70 - 100

Glucose (PP) 151.00 mg/dL 70 - 140

Note
1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2
hr post glucose value of > or = 200 mg/dL on at least 2 occasions

2. Very low glucose levels cause severe CNS dysfunction

3. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered
critical

Interpretation
---------------------------------------------------------------------------
| Status | Fasting plasma glucose | PP plasma glucose |
| | in mg/dL | in mg/dL |
|---------------------------|------------------------|----------------------|
| Normal | 70-100 | 70-140 |
|---------------------------|------------------------|----------------------|
| Impaired fasting glucose | 101-125 | 70-140 |
|---------------------------|------------------------|----------------------|
| Impaired glucose tolerance| 70-100 | 141-199 |
|---------------------------|------------------------|----------------------|
| Pre-Diabetes | 101-125 | 141-199 |
|---------------------------|------------------------|----------------------|
| Diabetes mellitus | >126 | >200 |
---------------------------------------------------------------------------

Dr Aashit Yadav Dr Rachna Malik

MBBS, MD Pathology MD, Pathology
Chief of Lab Consultant Pathologist
Dr Lal PathLabs Ltd

*172309386*
Page 4 of 5
.

Name : DGEHS-243769-MR VIRENDER SINGH

Lab No. : 172309386 Age : 64 Years
Ref By : SELF.... Gender : Male
Collected : 4/2/2023 9:00:00AM Reported : 4/2/2023 2:57:28PM
A/c Status : P Report Status : Final
Collected at : WALK IN PSC HANUMAN ROAD Processed at : LPL-VASANT KUNJ LAB
REGAL BUILDING CANNUAGHT PLACE-110001 NELSON MANDELA MARG, BUILDING No.1,
L.S.C., SECTOR-B, POCKET-7, VASANT
KUNJ, NEW DELHI-110070

Test Report

Test Name Results Units Bio. Ref. Interval

-------------------------------End of report --------------------------------
AHEEEHAPMKHJAOHNLCIDBJLCBILLJCECCJICIKPJPKEDFJFAPPAHEEEHA
BNFFFNBPAPBKBGMGFGEDEOAPAOAHFHALAOJOBCJOFLEKMOJHMPBNFFFNB
CIEGAAFJJOPMLBBOPFIAAJHFJEHEHEDHLKPHENFLMLKIOEFLBLGDEHANP
DJJAOEFNBBCIEDIDNKOELFMFANHKAKAFJIFFOAPAKCLJPDNLIDNBKEMEK
JDBKLHFJOFNFDIALMKGCKPJKAENJMJKHKKMHCCEIPLKGKPNGKFFFOKKMH
IJCBBEFMNICGDIFKIHIEOIPBADHFOFAINDFCBKDLBLIKONNALNEJOOECL
DPIMIJFNALOGDDGIEKMIBEEHIHAFJBAKOLEPBLMKOJCHKJFEIJNFMDILD
NJJJAMFMALOABALJGANHDIIILLBMFMBJOFCCAMNNIIKNOPNOBNFMAHILL
NKFDPLFINLKGFAAJBPNIHMEKHGFFEKFBJFFKBLOFOOBIOCNKDJPHNEKLJ
NPAIEKFCEDJJJDCKBPEFGPNAKDFKPNJHKEPFALNLNKCKIGEOCIPKHKAKL
KBIKOLFLGKCBMNBMPBNBPJEEINMLFKBBJNFEBFOEONDMKPFKEPCIGCAEO
ECICGJFCPLDBFMCMHHGCGNAEIEOPPFOFAENPBLNOOLJBIKNJPKONHDICL
MNNNNNEPKFALKKOJOCFLHEEHJBAHFHAJPKPFCMNLMKJCLFNOAHFHAHIKL
APBBBPAPBHKAEJBKFMDKCJCFAHFCHHCAONFEOKPGOLMHNLNNEDFHHBKHH
HHHHHHHPHHHPHPPHPPPPPPHHPPPPPPPPPPPHHPHPPHHHPHPHHHHPPHPHP

IMPORTANT INSTRUCTIONS
ŸTest results released pertain to the specimen submitted .ŸAll test results are dependent on the quality of the sample received by the Laboratory .
ŸLaboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .ŸReport
delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted .ŸCertain tests may require further testing at additional cost
for derivation of exact value. Kindly submit request within 72 hours post reporting.ŸTest results may show interlaboratory variations .ŸThe
Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes /claims concerning the test(s) & or results of test(s).ŸTest results are not valid
for medico legal purposes.ŸThis is computer generated medical diagnostic report that has been validated by Authorized Medical
Practitioner/Doctor. ŸThe report does not need physical signature.
(#) Sample drawn from outside source.
If Test results are alarming or unexpected, client is advised to contact the Customer Care immediately for possible remedial action.
Tel: +91-11-49885050,Fax: - +91-11-2788-2134, E-mail: lalpathlabs@lalpathlabs.com

*172309386*
Page 5 of 5